NAD+ and Aging: Why Your Cellular Coenzyme Matters
By Charles Kamen, MD, board-certified neurologist
By middle age, most people have lost roughly half of their baseline NAD+ (nicotinamide adenine dinucleotide) — one of the most abundant and essential coenzymes in every living cell, central to energy metabolism, DNA repair, cellular signaling, and mitochondrial function. Researchers now link that decline to multiple hallmarks of aging.
Dr. Charles Kamen, MD, board-certified neurologist at LiveNow Longevity in Las Vegas, treats NAD+ restoration as a foundational tool in longevity and cellular-health care. This article explains the science, the human evidence, and what NAD+ therapy actually involves. Individual results vary.
What Is NAD+ and Why Does It Decline?
NAD+ is a coenzyme found in every living cell that acts as an electron carrier in redox reactions — the metabolic steps that convert food into cellular energy (ATP). Without NAD+, the mitochondrial electron transport chain cannot function and ATP production collapses, which is why the molecule sits at the center of how cells make energy. [2]
Beyond energy production, NAD+ is consumed by enzymes called sirtuins, which regulate DNA repair, inflammation, and cellular stress resistance. PARP enzymes — essential for repairing single- and double-strand DNA breaks — also depend on it. Because one molecule fuels both energy and repair, a shortage forces the cell to ration between them. [3]
The decline with age is driven by several factors at once: chronic inflammation activates the NAD+-consuming enzymes PARP and CD38, oxidative stress rises, and biosynthesis through the salvage pathway slows. The result is a widening gap between how much NAD+ a cell needs and how much it can produce. [4]
What Is the Evidence for NAD+ Restoration?
In preclinical studies, raising NAD+ levels extends healthspan and lifespan in mice — restoring mitochondrial function, reactivating muscle stem cells, and protecting against diet-induced obesity. Human trials are earlier, but a growing body of evidence shows that oral precursors reliably raise NAD+ in people. [5]
The human data are accumulating:
- NMN supplementation: A 2022 randomized controlled trial in middle-aged adults found that a 10-week course of oral NMN increased skeletal muscle NAD+ content and improved aerobic capacity. [6]
- NR supplementation: Oral nicotinamide riboside (NR) reliably increases NAD+ in blood and skeletal muscle. [7] A randomized controlled trial in older adults confirmed that chronic NR safely and sustainably elevates NAD+ levels. [10]
- Larger clinical trials: NR is now being tested in specific conditions — the NICE trial evaluated nicotinamide riboside in patients with peripheral artery disease. [11]
- NAD+ IV therapy: Intravenous NAD+ delivers the coenzyme directly to the bloodstream. Limited peer-reviewed data exist on IV-specific outcomes, though NAD+ IV has been used clinically for decades in addiction medicine and Parkinson's disease. [8]
NAD+ IV Therapy vs. Oral Precursors
The two main delivery routes work differently:
IV NAD+: Delivers NAD+ directly into the bloodstream, bypassing the digestive system, typically as a slow infusion over 2-4 hours. Dr. Kamen uses it for patients seeking direct cellular support, and some report notable energy improvements within 24-48 hours.
Oral precursors (NMN, NR): Compounds the body converts to NAD+ through the salvage pathway. They are more convenient, less expensive, and backed by the growing clinical evidence above — NMN alone is the subject of more than 20 active registered clinical trials. [9]
Many longevity physicians, including Dr. Kamen, combine the two — IV NAD+ for an initial loading phase, followed by oral precursor maintenance.
How Does NAD+ Affect Energy and Recovery?
Because NAD+ powers the mitochondrial electron transport chain, restoring it targets the flagging energy and slower recovery that track with age. In mice, NAD+ repletion reactivated muscle stem cells and improved mitochondrial function; in the human NMN trial, ten weeks of supplementation raised muscle NAD+ and improved aerobic capacity. [5][6]
When NAD+ falls, cellular energy output drops and tissues recover less efficiently from exertion. Rebuilding it supports the machinery behind daytime energy, physical recovery, and the muscle maintenance that protects long-term healthspan.
NAD+, the Brain, and Cognition (A Neurologist's View)
The brain is one of the body's most energy-hungry organs, and it relies heavily on NAD+ to fuel neurons and support repair. An early randomized trial of nicotinamide riboside in people with mild cognitive impairment examined its effects on cognition and Alzheimer's-related biomarkers — an area Dr. Kamen follows closely as a neurologist. [12]
Neurons cannot store much fuel, so they rely on continuous mitochondrial output; when NAD+ is scarce, that output falters and can surface as mental fatigue and brain fog. NAD+ IV has also been used clinically for decades in Parkinson's disease and addiction medicine, conditions in which nervous-system energy metabolism is strained. [8]
The human cognitive data are still early, and NAD+ therapy is not a treatment for any neurological disease — but energy and repair for the body's most metabolically demanding tissue fits naturally into a longevity practice built around brain and metabolic health.
What Does NAD+ Therapy Involve?
NAD+ therapy at LiveNow Longevity typically starts with comprehensive biomarker testing, then a personalized plan: IV NAD+, oral NMN or NR, or a combination. IV infusions run over 2-4 hours; some patients report increased energy within 24-72 hours, while oral precursor benefits usually accumulate over two to four weeks of consistent use.
Because NAD+ is foundational to cellular metabolism, it generally complements other longevity therapies — peptide protocols, metabolic and weight support, and hormone optimization — rather than conflicting with them. Dr. Kamen reviews your labs, symptoms, and current treatments before recommending a route and cadence, then adjusts based on how you respond. Individual results vary.
Key Takeaways
- NAD+ declines roughly 50% between ages 40 and 60, impairing mitochondrial function, DNA repair, and cellular signaling.
- Preclinical studies show NAD+ restoration extends healthspan in mice; human trials are earlier but steadily accumulating.
- A 2022 randomized trial found a 10-week course of oral NMN raised skeletal muscle NAD+ and improved aerobic capacity.
- Randomized human trials confirm oral NR reliably elevates NAD+ in older adults, with larger trials now testing specific outcomes.
- IV NAD+ (a 2-4 hour infusion) and oral NMN/NR are both viable routes with different convenience and risk/benefit profiles.
- NAD+ IV therapy and biomarker-guided precursor plans are available at LiveNow Longevity in Las Vegas.
Common Questions
How soon will I notice results from NAD+ therapy?
Some patients report increased mental clarity and energy within 24-72 hours of an IV NAD+ infusion, though this is patient-reported and varies. Benefits from oral NMN or NR tend to accumulate more gradually, over roughly two to four weeks of consistent use. Dr. Kamen sets expectations individually based on your labs and goals.
Is NAD+ IV therapy safe?
NAD+ IV is generally well-tolerated when administered by an experienced physician. The most common side effects — flushing, nausea, or chest tightness during the infusion — are usually mild and resolve by slowing the drip or adjusting the dose. Dr. Kamen supervises infusions and screens for contraindications beforehand.
Can NAD+ therapy help with energy and brain fog?
NAD+ powers the mitochondrial electron transport chain that supplies cellular energy, and the brain is especially energy-dependent. Restoring NAD+ supports the machinery behind daytime energy and mental clarity, which is why many patients pursue it for fatigue and brain fog. Human cognitive data remain early, and individual results vary.
Should I choose IV NAD+ or oral NMN and NR?
It depends on your goals, budget, and how your body responds. IV NAD+ delivers the coenzyme directly and is often used for an initial loading phase; oral NMN or NR is more convenient, less expensive, and backed by growing clinical evidence. Many patients, guided by Dr. Kamen, combine both approaches.
Can I test my NAD+ levels?
Yes. LiveNow Longevity's comprehensive longevity lab panel includes NAD+ precursor and metabolite testing. Measuring your baseline lets Dr. Kamen individualize the restoration strategy — IV, oral precursors, or a combination — and track how your levels and symptoms respond over time rather than guessing at a protocol.
How does NAD+ interact with my other treatments?
NAD+ is foundational to cellular metabolism and generally complements other longevity therapies, including peptide protocols, weight and metabolic support, and hormone optimization. It is rarely a standalone fix. Dr. Kamen reviews every concurrent medication and supplement during consultation to build a coherent, non-conflicting plan.
NAD+ restoration is one of the most scientifically grounded longevity interventions available today — the preclinical data are compelling and human trials are steadily maturing. Learn about our NAD+ therapy protocols or schedule a consultation to discuss whether NAD+ fits your plan.
References
- Goodpaster BH, et al. J Gerontol A Biol Sci Med Sci. 2022;77(11):2175-2184.
- Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464-471.
- Covarrubias AJ, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119-141.
- Zhang H, et al. NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science. 2016;352(6292):1436-1443.
- Igarashi M, et al. Nat Commun. 2022;13:3658.
- Trammell SAJ, et al. Nat Commun. 2016;7:12948.
- Braidy N, Liu Y. Exp Gerontol. 2020;132:110831. (NAD+ therapy in age-related degenerative disorders: a benefit/risk analysis).
- ClinicalTrials.gov. Search: NMN OR nicotinamide mononucleotide. 2024.
- Martens CR, et al. Nat Commun. 2018;9:1286. (Chronic nicotinamide riboside elevates NAD+ in older adults, RCT).
- McDermott MM, et al. Nat Commun. 2024;15(1):6890. (NICE trial, nicotinamide riboside for peripheral artery disease).
- Wu CY, et al. Alzheimers Dement (N Y). 2025;11(1). (Nicotinamide riboside in MCI: cognitive and AD-biomarker effects).
Wondering what’s right for you?
Get a straight answer from board-certified neurologist Dr. Charles Kamen, MD. The evaluation is $88 and is applied toward your protocol if you continue care.